Published in Psychopharmacology (Berl) on July 09, 2013
Effects of striatal ΔFosB overexpression and ketamine on social defeat stress-induced anhedonia in mice. Biol Psychiatry (2014) 1.54
Stress-Induced Reinstatement of Drug Seeking: 20 Years of Progress. Neuropsychopharmacology (2015) 1.17
The darkness within: individual differences in stress. Cerebrum (2015) 1.05
Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism. Mol Pharmacol (2015) 1.01
Stress and VTA synapses: implications for addiction and depression. Eur J Neurosci (2014) 0.99
Abnormal error processing in depressive states: a translational examination in humans and rats. Transl Psychiatry (2015) 0.93
Orexin/hypocretin role in reward: implications for opioid and other addictions. Br J Pharmacol (2014) 0.92
Does the kappa opioid receptor system contribute to pain aversion? Front Pharmacol (2014) 0.92
Pharmacology and anti-addiction effects of the novel κ opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A. Br J Pharmacol (2014) 0.89
Poststress block of kappa opioid receptors rescues long-term potentiation of inhibitory synapses and prevents reinstatement of cocaine seeking. Biol Psychiatry (2014) 0.88
A novel method for analyzing extremely biased agonism at G protein-coupled receptors. Mol Pharmacol (2015) 0.87
Anxiety disorders and GABA neurotransmission: a disturbance of modulation. Neuropsychiatr Dis Treat (2015) 0.86
Novel approaches for the treatment of psychostimulant and opioid abuse - focus on opioid receptor-based therapies. Expert Opin Drug Discov (2014) 0.82
Kappa Opioid Receptor-Induced Aversion Requires p38 MAPK Activation in VTA Dopamine Neurons. J Neurosci (2015) 0.82
Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice. Psychopharmacology (Berl) (2014) 0.82
Effects of acute and chronic social defeat stress are differentially mediated by the dynorphin/kappa-opioid receptor system. Behav Pharmacol (2015) 0.81
Cellular and behavioral outcomes of dorsal striatonigral neuron ablation: new insights into striatal functions. Neuropsychopharmacology (2014) 0.81
Test-retest reproducibility of binding parameters in humans with 11C-LY2795050, an antagonist PET radiotracer for the κ opioid receptor. J Nucl Med (2015) 0.81
Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse. Adv Pharmacol (2014) 0.81
Role of the Brain's Reward Circuitry in Depression: Transcriptional Mechanisms. Int Rev Neurobiol (2015) 0.80
Kir3 channel signaling complexes: focus on opioid receptor signaling. Front Cell Neurosci (2014) 0.80
Molecular Pharmacology of δ-Opioid Receptors. Pharmacol Rev (2016) 0.80
Characterization of kappa opioid receptor mediated, dynorphin-stimulated [(35)S]GTPγS binding in mouse striatum for the evaluation of selective KOR ligands in an endogenous setting. Neuropharmacology (2015) 0.79
The role of the dynorphin/κ opioid receptor system in anxiety. Acta Pharmacol Sin (2015) 0.79
Relative Timing Between Kappa Opioid Receptor Activation and Cocaine Determines the Impact on Reward and Dopamine Release. Neuropsychopharmacology (2015) 0.79
Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice. Neuropharmacology (2015) 0.79
Repeated stress exposure causes strain-dependent shifts in the behavioral economics of cocaine in rats. Addict Biol (2014) 0.79
Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials. Depress Anxiety (2016) 0.78
Chew the Pain Away: Oral Habits to Cope with Pain and Stress and to Stimulate Cognition. Biomed Res Int (2015) 0.77
Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice. J Psychopharmacol (2015) 0.77
Naltrexone alters the processing of social and emotional stimuli in healthy adults. Soc Neurosci (2016) 0.77
Anxiolytic- and antidepressant-like effects of the methadone metabolite 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP). Neuropharmacology (2015) 0.77
Pituitary Adenylate Cyclase-Activating Polypeptide Disrupts Motivation, Social Interaction, and Attention in Male Sprague Dawley Rats. Biol Psychiatry (2015) 0.77
Opposing roles of cotransmission of dynorphin and hypocretin on reward and motivation. Proc Natl Acad Sci U S A (2014) 0.77
Drug withdrawal conceptualized as a stressor. Behav Pharmacol (2014) 0.77
The affective dimension of pain as a risk factor for drug and alcohol addiction. Alcohol (2015) 0.77
A Trigger for Opioid Misuse: Chronic Pain and Stress Dysregulate the Mesolimbic Pathway and Kappa Opioid System. Front Neurosci (2016) 0.77
How does stress-induced activation of the kappa opioid system increase addiction risk? Biol Psychiatry (2014) 0.76
Opiates Modulate Noxious Chemical Nociception through a Complex Monoaminergic/Peptidergic Cascade. J Neurosci (2016) 0.76
Prefrontal Cortical Kappa Opioid Receptors Attenuate Responses to Amygdala Inputs. Neuropsychopharmacology (2015) 0.76
Influence of stress associated with chronic alcohol exposure on drinking. Neuropharmacology (2017) 0.75
Age-dependent regulation of GABA transmission by kappa opioid receptors in the basolateral amygdala of Sprague-Dawley rats. Neuropharmacology (2017) 0.75
Pyrrolo- and pyridomorphinans: non-selective opioid antagonists and delta opioid agonists/mu opioid partial agonists. Bioorg Med Chem (2014) 0.75
Constitutive activation of kappa opioid receptors at ventral tegmental area inhibitory synapses following acute stress. Elife (2017) 0.75
Social disruption alters pain and cognition in an animal model of multiple sclerosis. J Neuroimmunol (2015) 0.75
A Possible Role of Anhedonia as Common Substrate for Depression and Anxiety. Depress Res Treat (2016) 0.75
Kappa Opioids, Salvinorin A and Major Depressive Disorder. Curr Neuropharmacol (2016) 0.75
Kappa-opioid receptors differentially regulate low and high levels of ethanol intake in female mice. Brain Behav (2016) 0.75
The anti-suicidal potential of buprenorphine: a case report. Int J Psychiatry Med (2014) 0.75
Binding mode analyses of NAP derivatives as mu opioid receptor selective ligands through docking studies and molecular dynamics simulation. Bioorg Med Chem (2017) 0.75
Two short-acting kappa opioid receptor antagonists (zyklophin and LY2444296) exhibited different behavioral effects from the long-acting antagonist norbinaltorphimine in mouse anxiety tests. Neurosci Lett (2016) 0.75
Effects of naltrexone are influenced by childhood adversity during negative emotional processing in addiction recovery. Transl Psychiatry (2017) 0.75
Transcriptome of neonatal preBötzinger complex neurones in Dbx1 reporter mice. Sci Rep (2017) 0.75
Role of the Dynorphin/Kappa Opioid Receptor System in the Motivational Effects of Ethanol. Alcohol Clin Exp Res (2017) 0.75
Effects of chronic social defeat stress on sleep and circadian rhythms are mitigated by kappa-opioid receptor antagonism. J Neurosci (2017) 0.75
Neuroclinical Framework for the Role of Stress in Addiction. Chronic Stress (Thousand Oaks) (2017) 0.75
The anxiolytic- and antidepressant-like effects of ATPM-ET, a novel κ agonist and μ partial agonist, in mice. Psychopharmacology (Berl) (2016) 0.75
Neurocircuitry of addiction. Neuropsychopharmacology (2010) 14.22
Genetics of mouse behavior: interactions with laboratory environment. Science (1999) 10.74
Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science (1981) 9.64
Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science (2006) 9.31
Depression: a new animal model sensitive to antidepressant treatments. Nature (1977) 8.76
Causal relationship between stressful life events and the onset of major depression. Am J Psychiatry (1999) 7.84
The mesolimbic dopamine reward circuit in depression. Biol Psychiatry (2006) 7.62
The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA (1992) 6.96
A psychomotor stimulant theory of addiction. Psychol Rev (1987) 6.42
The effects of stressful life events on depression. Annu Rev Psychol (1997) 5.98
The many faces of CREB. Trends Neurosci (2005) 5.58
Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr Rev (1984) 5.36
The projections of the ventral tegmental area and adjacent regions: a combined fluorescent retrograde tracer and immunofluorescence study in the rat. Brain Res Bull (1983) 5.23
Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res (2002) 4.93
The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology (Berl) (2002) 4.78
Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology (1983) 4.67
Input-specific control of reward and aversion in the ventral tegmental area. Nature (2012) 4.60
Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology (2007) 4.38
Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am J Psychiatry (2007) 4.37
A continuous performance test of brain damage. J Consult Psychol (1956) 4.26
Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol (2000) 4.17
Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology (1985) 4.11
Role of the bed nucleus of the stria terminalis versus the amygdala in fear, stress, and anxiety. Eur J Pharmacol (2003) 4.08
Regulation of cocaine reward by CREB. Science (1998) 4.07
Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science (1982) 3.80
Trajectories of brain development: point of vulnerability or window of opportunity? Neurosci Biobehav Rev (2003) 3.76
Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci (2003) 3.64
Limbic system mechanisms of stress regulation: hypothalamo-pituitary-adrenocortical axis. Prog Neuropsychopharmacol Biol Psychiatry (2005) 3.61
Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) (1995) 3.61
Psychotomimesis mediated by kappa opiate receptors. Science (1986) 3.60
The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J Neurosci (2008) 3.54
Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther (2003) 3.48
Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet (1998) 3.42
CREB activity in the nucleus accumbens shell controls gating of behavioral responses to emotional stimuli. Proc Natl Acad Sci U S A (2002) 3.32
Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons. Nature (2012) 3.15
Drug addiction: the neurobiology of behaviour gone awry. Nat Rev Neurosci (2004) 3.13
Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet (2000) 3.10
Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accumbens. J Neurosci (2001) 3.09
Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron (1998) 3.08
Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci U S A (1992) 3.02
Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol (2000) 2.95
Dopamine neurons modulate neural encoding and expression of depression-related behaviour. Nature (2012) 2.88
Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science (1984) 2.83
Anatomy of CNS opioid receptors. Trends Neurosci (1988) 2.82
Biological substrates of reward and aversion: a nucleus accumbens activity hypothesis. Neuropharmacology (2008) 2.80
Properties and opioid inhibition of mesolimbic dopamine neurons vary according to target location. J Neurosci (2006) 2.80
Neuroendocrine pharmacology of stress. Eur J Pharmacol (2003) 2.77
Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontal cortex. J Neurochem (1989) 2.75
Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther (2005) 2.66
Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology (Berl) (2005) 2.60
Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain. J Neurosci (1987) 2.53
Stress-induced p38 mitogen-activated protein kinase activation mediates kappa-opioid-dependent dysphoria. J Neurosci (2007) 2.51
Research Domain Criteria: cognitive systems, neural circuits, and dimensions of behavior. Dialogues Clin Neurosci (2012) 2.45
Dynorphin, stress, and depression. Brain Res (2009) 2.45
Basic organization of projections from the oval and fusiform nuclei of the bed nuclei of the stria terminalis in adult rat brain. J Comp Neurol (2001) 2.45
Corticotropin-releasing factor, norepinephrine, and stress. Biol Psychiatry (1999) 2.39
Mesolimbic dopaminergic pathways in fear conditioning. Prog Neurobiol (2004) 2.38
The role of stress in drug self-administration. Trends Pharmacol Sci (1998) 2.36
Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology (Berl) (2004) 2.35
Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther (1988) 2.29
Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex. Proc Natl Acad Sci U S A (2006) 2.29
Midbrain dopamine neurons: projection target determines action potential duration and dopamine D(2) receptor inhibition. J Neurosci (2008) 2.28
Organization of projections from the medial nucleus of the amygdala: a PHAL study in the rat. J Comp Neurol (1995) 2.28
Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res (1993) 2.27
Stress-induced and alcohol cue-induced craving in recently abstinent alcohol-dependent individuals. Alcohol Clin Exp Res (2007) 2.24
Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry (1997) 2.22
Kappa-opioid agonists directly inhibit midbrain dopaminergic neurons. J Neurosci (2003) 2.21
The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology (Berl) (2010) 2.19
Uncontrollability and unpredictability in post-traumatic stress disorder: an animal model. Psychol Bull (1992) 2.13
Neurobiology of resilience. Nat Neurosci (2012) 2.13
Fear conditioning, synaptic plasticity and the amygdala: implications for posttraumatic stress disorder. Trends Neurosci (2011) 2.12
Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats. J Pharmacol Exp Ther (2007) 2.06
Parallel circuits mediating distinct emotional coping reactions to different types of stress. Neurosci Biobehav Rev (2001) 2.06
CRF-CRF1 system activation mediates withdrawal-induced increases in nicotine self-administration in nicotine-dependent rats. Proc Natl Acad Sci U S A (2007) 2.01
The involvement of nucleus accumbens dopamine in appetitive and aversive motivation. Behav Brain Res (1994) 2.01
Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J Pharmacol Exp Ther (1993) 2.01
Kappa opioid receptor activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes. J Biol Chem (2006) 1.97
Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. Am J Psychiatry (1999) 1.96
Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. J Neurochem (2004) 1.96
Social stress, therapeutics and drug abuse: preclinical models of escalated and depressed intake. Pharmacol Ther (2008) 1.94
Differential steroid hormone and neural influences on peptide mRNA levels in CRH cells of the paraventricular nucleus: a hybridization histochemical study in the rat. J Comp Neurol (1989) 1.92
Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase. J Biol Chem (2007) 1.91
Kinase cascades and ligand-directed signaling at the kappa opioid receptor. Psychopharmacology (Berl) (2010) 1.90
Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect. J Neurosci (2002) 1.89
The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Nucl Recept Signal (2007) 1.89
Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test. J Pharmacol Exp Ther (1992) 1.88
Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking. Proc Natl Acad Sci U S A (2009) 1.88
Neurobiology of fear responses: the role of the amygdala. J Neuropsychiatry Clin Neurosci (1997) 1.84
The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci (2002) 1.84
Selective p38α MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction. Neuron (2011) 1.83
Ventral subicular interaction with the hypothalamic paraventricular nucleus: evidence for a relay in the bed nucleus of the stria terminalis. J Comp Neurol (1993) 1.83
Stress reinstates heroin-seeking in drug-free animals: an effect mimicking heroin, not withdrawal. Psychopharmacology (Berl) (1995) 1.82
Prior activation of kappa opioid receptors by U50,488 mimics repeated forced swim stress to potentiate cocaine place preference conditioning. Neuropsychopharmacology (2006) 1.81
Primary structure of corticotropin-releasing factor from ovine hypothalamus. Proc Natl Acad Sci U S A (1981) 1.78
Corticotropin-releasing factor receptors are widely distributed within the rat central nervous system: an autoradiographic study. J Neurosci (1985) 1.77
Distribution of glucocorticoid receptor immunoreactivity and mRNA in the rat brain: an immunohistochemical and in situ hybridization study. Neurosci Res (1996) 1.70
Stress, Glucocorticoids, and Damage to the Nervous System: The Current State of Confusion. Stress (1996) 1.70
Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci U S A (2000) 1.69
Stress-induced reinstatement of cocaine seeking is mediated by the kappa opioid system. Psychopharmacology (Berl) (2008) 1.68
Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. J Neurosci (1994) 1.65
The mesolimbic dopamine reward circuit in depression. Biol Psychiatry (2006) 7.62
Mania-like behavior induced by disruption of CLOCK. Proc Natl Acad Sci U S A (2007) 3.92
Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther (2003) 3.48
GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat Med (2006) 3.38
Dynorphin, stress, and depression. Brain Res (2009) 2.45
Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology (Berl) (2004) 2.35
Fear conditioning occludes LTP-induced presynaptic enhancement of synaptic transmission in the cortical pathway to the lateral amygdala. Neuron (2002) 2.34
Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats. J Pharmacol Exp Ther (2007) 2.06
Synthesis and in vitro pharmacological studies of new C(2) modified salvinorin A analogues. Bioorg Med Chem Lett (2005) 1.79
D-cycloserine effects on extinction of conditioned responses to drug-related cues. Biol Psychiatry (2012) 1.72
Essential role for TRPC5 in amygdala function and fear-related behavior. Cell (2009) 1.72
Development of κ opioid receptor antagonists. J Med Chem (2013) 1.61
Synthesis and in vitro pharmacological evaluation of salvinorin A analogues modified at C(2). Bioorg Med Chem Lett (2005) 1.60
NMDA receptors regulate nicotine-enhanced brain reward function and intravenous nicotine self-administration: role of the ventral tegmental area and central nucleus of the amygdala. Neuropsychopharmacology (2008) 1.57
CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy. Psychopharmacology (Berl) (2011) 1.57
Altered responsiveness to cocaine in rats exposed to methylphenidate during development. Nat Neurosci (2002) 1.56
Synthesis and in vitro evaluation of salvinorin A analogues: effect of configuration at C(2) and substitution at C(18). Bioorg Med Chem Lett (2006) 1.55
Glutamate receptors in extinction and extinction-based therapies for psychiatric illness. Neuropsychopharmacology (2010) 1.51
Use of herpes virus amplicon vectors to study brain disorders. Biotechniques (2005) 1.43
Synthesis and in vitro pharmacological studies of C(4) modified salvinorin A analogues. Bioorg Med Chem Lett (2005) 1.34
Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats. Biol Psychiatry (2011) 1.33
Effects of pain- and analgesia-related manipulations on intracranial self-stimulation in rats: further studies on pain-depressed behavior. Pain (2009) 1.32
Reward-aversion circuitry in analgesia and pain: implications for psychiatric disorders. Eur J Pain (2006) 1.31
The kappa-opioid agonist U69,593 blocks cocaine-induced enhancement of brain stimulation reward. Biol Psychiatry (2008) 1.31
Altered sensitivity to rewarding and aversive drugs in mice with inducible disruption of cAMP response element-binding protein function within the nucleus accumbens. J Neurosci (2009) 1.30
Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats. Neuropharmacology (2011) 1.29
Altered attention and prefrontal cortex gene expression in rats after binge-like exposure to cocaine during adolescence. J Neurosci (2006) 1.22
Behavioral and anatomical interactions between dopamine and corticotropin-releasing factor in the rat. J Neurosci (2006) 1.22
Duration of action of a broad range of selective κ-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation. Mol Pharmacol (2011) 1.20
Extinction of drug- and withdrawal-paired cues in animal models: relevance to the treatment of addiction. Neurosci Biobehav Rev (2010) 1.19
Brain reward regulated by AMPA receptor subunits in nucleus accumbens shell. J Neurosci (2006) 1.17
Behavioral and molecular effects of dopamine D1 receptor stimulation during naloxone-precipitated morphine withdrawal. J Neurosci (2006) 1.17
Activation of CREB in the nucleus accumbens shell produces anhedonia and resistance to extinction of fear in rats. J Neurosci (2011) 1.16
Synthesis and in vitro pharmacological studies of new C(4)-modified salvinorin A analogues. Bioorg Med Chem Lett (2006) 1.16
Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem (2007) 1.15
8-epi-Salvinorin B: crystal structure and affinity at the kappa opioid receptor. Beilstein J Org Chem (2007) 1.14
Elevated expression of 5-HT1B receptors in nucleus accumbens efferents sensitizes animals to cocaine. J Neurosci (2002) 1.14
New neoclerodane diterpenoids isolated from the leaves of Salvia divinorum and their binding affinities for human kappa opioid receptors. Bioorg Med Chem (2005) 1.13
D-cycloserine facilitates extinction of naloxone-induced conditioned place aversion in morphine-dependent rats. Biol Psychiatry (2010) 1.11
Repeated exposure to the κ-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity. Biol Psychiatry (2011) 1.10
The selective non-peptidic delta opioid agonist SNC80 does not facilitate intracranial self-stimulation in rats. Eur J Pharmacol (2008) 1.09
Hypocretin (orexin) facilitates reward by attenuating the antireward effects of its cotransmitter dynorphin in ventral tegmental area. Proc Natl Acad Sci U S A (2014) 1.08
Desipramine reduces stress-activated dynorphin expression and CREB phosphorylation in NAc tissue. Mol Pharmacol (2008) 1.08
Exposure to the selective kappa-opioid receptor agonist salvinorin A modulates the behavioral and molecular effects of cocaine in rats. Neuropsychopharmacology (2008) 1.07
Sensitivity of the five-choice serial reaction time task to the effects of various psychotropic drugs in Sprague-Dawley rats. Biol Psychiatry (2007) 1.07
Cocaine and SKF-82958 potentiate brain stimulation reward in Swiss-Webster mice. Psychopharmacology (Berl) (2002) 1.06
Transient overexpression of alpha-Ca2+/calmodulin-dependent protein kinase II in the nucleus accumbens shell enhances behavioral responding to amphetamine. J Neurosci (2010) 1.05
Early developmental exposure to methylphenidate reduces cocaine-induced potentiation of brain stimulation reward in rats. Biol Psychiatry (2005) 1.05
Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues. Bioorg Med Chem Lett (2011) 1.03
Schizophrenia-like attentional deficits following blockade of prefrontal cortex GABAA receptors. Neuropsychopharmacology (2011) 1.01
Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats. Psychopharmacology (Berl) (2010) 1.00
Blockade of astrocytic glutamate uptake in rats induces signs of anhedonia and impaired spatial memory. Neuropsychopharmacology (2010) 1.00
Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor. Bioorg Med Chem (2008) 0.99
CREB gene transcription factors: role in molecular mechanisms of alcohol and drug addiction. Alcohol Clin Exp Res (2005) 0.98
Coactivation of thalamic and cortical pathways induces input timing-dependent plasticity in amygdala. Nat Neurosci (2011) 0.98
N-methylacetamide analog of salvinorin A: a highly potent and selective kappa-opioid receptor agonist with oral efficacy. J Pharmacol Exp Ther (2007) 0.98
Activation of raphe efferents to the medial prefrontal cortex by corticotropin-releasing factor: correlation with anxiety-like behavior. Biol Psychiatry (2007) 0.97
Blockade of astrocytic glutamate uptake in the prefrontal cortex induces anhedonia. Neuropsychopharmacology (2012) 0.97
Prenatal exposure to cocaine increases the rewarding potency of cocaine and selective dopaminergic agonists in adult mice. Biol Psychiatry (2007) 0.97
Ablation of kappa-opioid receptors from brain dopamine neurons has anxiolytic-like effects and enhances cocaine-induced plasticity. Neuropsychopharmacology (2013) 0.97
Role of the bed nucleus of the stria terminalis (BST) in the expression of conditioned fear. Ann N Y Acad Sci (2006) 0.96
Epinephrine: a short- and long-term regulator of stress and development of illness : a potential new role for epinephrine in stress. Cell Mol Neurobiol (2011) 0.95
Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity. BMC Pharmacol (2012) 0.95
Diazepam and cocaine potentiate brain stimulation reward in C57BL/6J mice. Behav Brain Res (2009) 0.95
Differential roles of GABA(A) receptor subtypes in benzodiazepine-induced enhancement of brain-stimulation reward. Neuropsychopharmacology (2012) 0.94
Effects of antipsychotic drugs on MK-801-induced attentional and motivational deficits in rats. Neuropharmacology (2009) 0.94
Corticotropin-releasing factor (CRF)-induced disruption of attention in rats is blocked by the κ-opioid receptor antagonist JDTic. Neuropsychopharmacology (2012) 0.93
Contribution of drug doses and conditioning periods to psychomotor stimulant sensitization. Psychopharmacology (Berl) (2006) 0.91
Dopamine-dependent increases in phosphorylation of cAMP response element binding protein (CREB) during precipitated morphine withdrawal in primary cultures of rat striatum. J Neurochem (2003) 0.91
LTP in the lateral amygdala during cocaine withdrawal. Eur J Neurosci (2006) 0.91
ΔFosB enhances the rewarding effects of cocaine while reducing the pro-depressive effects of the kappa-opioid receptor agonist U50488. Biol Psychiatry (2011) 0.91
Behavioral effects of short-term administration of lithium and valproic acid in rats. Brain Res (2006) 0.90
Learning and reconsolidation implicate different synaptic mechanisms. Proc Natl Acad Sci U S A (2013) 0.90
Attention deficits and hyperactivity following inhibition of cAMP-dependent protein kinase within the medial prefrontal cortex of rats. Neuropsychopharmacology (2009) 0.89
Microinjection of the L-type calcium channel antagonist diltiazem into the ventral nucleus accumbens shell facilitates cocaine-induced conditioned place preferences. Biol Psychiatry (2006) 0.88
Pituitary adenylate cyclase-activating polypeptide induces postsynaptically expressed potentiation in the intra-amygdala circuit. J Neurosci (2012) 0.88
Electroconvulsive seizures stimulate glial proliferation and reduce expression of Sprouty2 within the prefrontal cortex of rats. Biol Psychiatry (2007) 0.86
Roles of nucleus accumbens CREB and dynorphin in dysregulation of motivation. Cold Spring Harb Perspect Med (2013) 0.85
Anatomically dissociable effects of dopamine D1 receptor agonists on reward and relief of withdrawal in morphine-dependent rats. Psychopharmacology (Berl) (2009) 0.84
Reduction of fear-potentiated startle by benzodiazepines in C57BL/6J mice. Psychopharmacology (Berl) (2010) 0.82
Effects of acute and chronic social defeat stress are differentially mediated by the dynorphin/kappa-opioid receptor system. Behav Pharmacol (2015) 0.81
Lithium administration to preadolescent rats causes long-lasting increases in anxiety-like behavior and has molecular consequences. J Neurosci (2006) 0.81
Ion channels and intracellular signaling proteins as potential targets for novel therapeutics for addictive and depressive disorders. Pharmacol Ther (2005) 0.81
Amygdalar GABAergic-rich neural grafts attenuate anxiety-like behavior in rats. Behav Brain Res (2009) 0.81
Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder: a double-blind, randomized add-on clinical trial. J Clin Psychopharmacol (2012) 0.80
Selective κ opioid antagonists nor-BNI, GNTI and JDTic have low affinities for non-opioid receptors and transporters. PLoS One (2013) 0.80
Social defeat stress-induced sensitization and escalated cocaine self-administration: the role of ERK signaling in the rat ventral tegmental area. Psychopharmacology (Berl) (2014) 0.79
Extinction of conditioned opiate withdrawal in rats is blocked by intracerebroventricular infusion of an NMDA receptor antagonist. Neurosci Lett (2013) 0.79
Extinction of conditioned opiate withdrawal in rats in a two-chambered place conditioning apparatus. Nat Protoc (2012) 0.79
Lovastatin potentiates the antidepressant efficacy of fluoxetine in rats. Pharmacol Biochem Behav (2008) 0.79
Tracking down the molecular substrates of stress: new roles for p38α MAPK and kappa-opioid receptors. Neuron (2011) 0.79
Can't get enough of that dopamine. Am J Psychiatry (2007) 0.78
Ascent of the kappa-opioid receptor in psychopharmacology. Psychopharmacology (Berl) (2010) 0.78
Antidepressant effect of stem cell-derived monoaminergic grafts. Neuroreport (2007) 0.77
Glial abnormalities in mood disorders. Harv Rev Psychiatry (2014) 0.77
Corticotropin-releasing factor from the rat brain measured by protein immunoblot. Peptides (2005) 0.77
Drug withdrawal conceptualized as a stressor. Behav Pharmacol (2014) 0.77
Neuroscience. Illuminating the neural circuitry of compulsive behaviors. Science (2013) 0.76
Neuroinflammation and autism: toward mechanisms and treatments. Neuropsychopharmacology (2013) 0.76